|
One of the world’s leading researchers in cryobiology will return to his alma mater, SUNY Fredonia, for public presentations and informal talks Wednesday and Thursday, Nov. 5 and 6. A 1965 biology graduate, John G. Baust has studied strategies in low temperature biology that have led to new cancer therapies.
Dr. Baust, founder of BioLife Solutions, Inc., and director of the Institute of Biomedical Technology at SUNY Binghamton, will discuss how his career began as an undergraduate at SUNY Fredonia, continued through his doctoral research at the University of Alaska, and ultimately led to the development of a new cancer therapy.
Entitled, “From Bugs and Butterflies to Cancer Therapies,” his first talk will be given Wednesday, Nov. 5, at 4:30 p.m. in Jewett Hall Room 101. The public is invited.
On Thursday, Dr. Baust will present a technical seminar on a therapy used for treating prostate cancer that uses cold energy to kill tissue. This research seminar, entitled, “Cryoablation—A Marriage of Molecular and Biophysical-based Approaches to Cancer Therapy,” starts at 5 p.m. in Jewett Hall Room 101 and is open to the public.
During his two-day visit, Dr. Baust will also be a guest speaker in two classes: biochemistry, and mammalian physiology.
Dr. Baust is currently Editor-in-Chief of the journal, Cell Preservation Technology, and co-editor of the recent book, Advances in Biopreservation.
Prior to founding BioLife Solutions, Dr. Baust was senior vice president and chief scientific officer at Cryomedical Sciences, Inc.
Since 1987, he has been a biochemistry professor at SUNY Binghamton, and since 1994, an adjunct professor of surgery at the Medical College of Pennsylvania. From 1984 to 1987, Dr. Baust taught at the University of Houston, where he was also director of the Institute of Low Temperature Biology.
The company he founded, BioLife Solutions, engages in the development, manufacture, and marketing of proprietary hypothermic storage and cryopreservation solutions for cells, tissues, and organs. Its proprietary products are marketed to companies, laboratories, and academic institutions.
